Navigation Links
Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
Date:3/18/2009

TSX Venture: QPT

EDMONTON, March 18 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced that it has formed a strategic alliance with IntelligentNano Inc. and, as a result of the alliance, the two groups have created a water soluble nano-formulation of Quest's SL052 technology, which has the potential to address a wider range of clinical needs than Quest's current formulation of SL052.

"We have successfully used nanoparticles to make SL052 water soluble while maintaining the biological activity of the drug, whether activated by light or ultrasound," said Dr. Jie Chen, Chief Technology Officer for IntelligentNano, a spin-off company from the Canadian National Research Council's National Institute for Nanotechnology.

"The fulfillment of a second tier of targetable, water-soluble nano-formulations of the SonoLight compounds represents major progress in the adaptation of Hypocrellin-based photodynamic and sonodynamic therapy to a wide spectrum of clinical needs including cancer treatment," stated Dr. Madi R. Madiyalakan, Chief Executive Officer at Quest.

The alliance between Quest and IntelligentNano was forged to explore the potential of nanotechnology to provide a multiplicity of biocompatible drug delivery systems for clinical applications of Quest's proprietary SonoLight technology platform. Current SonoLight photosensitizer and sonosensitizer formulations are based upon liposomal drug delivery systems which target the drug to the desired sites of photodynamic or sonodynamic therapies. Quest intends to initiate a series of preclinical studies with these new formulations and arrive at a clinical plan for Quest's second cancer indication.

The results from the product development initiative will be presented at the prestigious Institute of El
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Beckman Coulter,Inc. (NYSE: BEC ), a ... automate, and innovate complex biomedical testing,announced today that ... Business Development, will present at the following,conferences:, ... -- Bank of America 2008 Healthcare Conference on ...
... in physician,s office -, MADISON, N.J., May ... Diagnostics Incorporated (NYSE: DGX ),today announced the ... fecal,immunochemical test, a point-of-care version of the company,s ... sensitivity and,specificity of the laboratory-based InSure FIT test., ...
... CE Mark Approval for First Product, the CorMatrix ... ECM(TM) for Pericardial ... based company dedicated to developing and delivering unique,extracellular matrix (ECM(TM)) ... cardiovascular tissue, announced,today that the company has received 510(k) clearance ...
Cached Biology Technology:Beckman Coulter to Present at Upcoming Healthcare Conferences 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... the Andes mountains of Ecuador have described a new plant ... itself a mini biodiversity hotspot. The new species, Piper ... insect species, most of which are entirely dependent on this ... larger project which focuses on the influence of plant-produced chemical ...
... factory built of gel does not sound very durable. But ... University do not have to last. They will actually ... medicine is required and they will gradually dissolve and ... The prospects are so enormous that Associate Professor of ...
... that generates the most scientific debate is the dating of ... the Spanish National Research Centre for Human Evolution, among others, ... , Journal of Archaeological Science , has clarified that the ... Homo antecessor were discovered in 1994, is 900,000 years ...
Cached Biology News:New plant species a microcosm of biodiversity 2Tiny soft medicine factories 2Dating is refined for the Atapuerca site where Homo antecessor appeared 2
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
... CUL-3 is a member of the family of human ... homologous to the S. cerevisiae cdc53 gene. Cullin-3 is ... It forms a tight complex with cyclin E and ... by protesomes. Cyclin E is an activator of cdk2, ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
Biology Products: